Last reviewed 2026-05-14 · How we verify

Estriol Cream 0.1%

Estriol is a weak estrogen that binds to estrogen receptors in vaginal and urogenital tissues to restore epithelial maturation and improve local tissue health.

Estriol is a weak estrogen that binds to estrogen receptors in vaginal and urogenital tissues to restore epithelial maturation and improve local tissue health. Used for Atrophic vaginitis and urogenital atrophy in postmenopausal women, Vaginal dryness and dyspareunia associated with menopause.

At a glance

Mechanism of action

Estriol is a naturally occurring estrogen that acts as an estrogen receptor agonist in vaginal and urogenital tissues. When applied topically as a cream, it promotes vaginal epithelial maturation, increases vaginal blood flow, and restores normal vaginal flora and pH, thereby alleviating symptoms of atrophic vaginitis and urogenital atrophy associated with menopause or estrogen deficiency.

Approved indications

• Atrophic vaginitis and urogenital atrophy in postmenopausal women
• Vaginal dryness and dyspareunia associated with menopause

Common side effects

• Vaginal irritation or burning
• Vaginal discharge
• Systemic estrogen absorption (minimal with topical application)

Key clinical trials

• Subtypes of Provoked Vestibulodynia
• Investigation of Non-inferiority of Treatment of Vulvovaginal Dryness With WO2085 Moisturising Cream in Comparison to a Cream With 0.1% Estriol (PHASE4)
• Postpartum Dyspareunia Resulting From Vaginal Atrophy

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Estriol Cream 0.1% CI brief — competitive landscape report
• Estriol Cream 0.1% updates RSS · CI watch RSS
• Dr. August Wolff GmbH & Co. KG Arzneimittel portfolio CI